Cofactor Genomics
-89%
est. 2Y upside i
Cofactor closes the precision medicine gap with predictive diagnostics
Rank
#3686
Sector
Biotechnology
Est. Liquidity
~3Y
Data Quality
Data: LowCofactor Genomics offers a high-risk equity opportunity with potential for zero return given the severe preference overhang ($28.7M on a ~$30M valuation) and high incumbent threat.
Last updated: July 3, 2026
If an IPO window opens or category leadership is established, exit multiple could expand to 10x, yielding a modest 9% upside after dilution and preference stack.
Exit multiple converges to 6x, but implied exit value of $23.2M falls below $28.7M preference, leaving common stock with -100% recovery.
Multiple compresses to 3x, exit value $11.6M far below preference, common stock worth zero.
Preference Stack Risk
severeFunding Intensity
96%Total funding of $28.7M is 95.7% of estimated entry valuation, meaning preferred shareholders have near-total liquidation preference.
Dilution Risk
highCompany's high capital intensity and low revenue suggest additional capital raises are likely, diluting common stock by 15-25%.
Secondary Liquidity
noneNo secondary trading activity observed; equity is illiquid.
Questions to Ask at the Interview
Strategic questions based on Cofactor Genomics's data — designed to show you've done your homework.
- 1
“How does Cofactor plan to differentiate from Foundation Medicine and Guardant Health in clinical adoption?”
- 2
“What is the company’s path to scaling revenue given the current $3.2M run rate?”
- 3
“Given the preference stack, what is the realistic outcome for common stock in an exit scenario?”
Community
Valuation Sentiment
Our model estimates -89% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.